Evidence method
Level · gp.fundamentals.debt_to_revenue
35.00% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Dec 31, 2018
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-19-010541General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
2.85% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
33.27% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
13.99% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
20.09% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
63.77% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
17.54% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
7.63% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.36% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 264.48%
- Current
- 35.00%
- Delta
- -229.48%
- Previous
- 2.71%
- Current
- 2.85%
- Delta
- 0.14%
- Previous
- 16.41%
- Current
- 33.27%
- Delta
- 16.87%
- Previous
- 5.27%
- Current
- 13.99%
- Delta
- 8.71%
- Previous
- 78.90%
- Current
- 20.09%
- Delta
- -58.81%
- Previous
- 69.22%
- Current
- 63.77%
- Delta
- -5.45%
- Previous
- 19.95%
- Current
- 17.54%
- Delta
- -2.41%
- Previous
- 9.20%
- Current
- 7.63%
- Delta
- -1.57%
- Previous
- 3.49%
- Current
- 3.36%
- Delta
- -0.13%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Analogous To · ANIP state analogue 5 →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP MARGIN_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.